A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

NCT07000617 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

NK/T Cell Lymphoma

Interventions

DRUG: DAPT regimen plus radiotherapy

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]
[object Object]